Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neoadjuvant Olaparib monotherapy group|COMBINATION_PRODUCT: Neoadjuvant combination therapy with olaparib plus durvalumab
Sponsor: AstraZeneca